Parabilis Medicines has appointed Craig L. Tendler, M.D., to its Board of Directors. Dr. Tendler previously led clinical development and medical affairs for oncology at Johnson & Johnson, where he helped secure more than 30 oncology regulatory approvals and 13 FDA Breakthrough Therapy designations. He will continue serving as a scientific advisor to Parabilis alongside his new board role. The company is advancing zolucatetide, its lead Helicon therapeutic, across multiple Wnt/β-catenin-driven indications.
Parabilis Medicines, Inc. Common StockAppointment of experienced board member strengthens governance and strategic oversight.
Johnson & Johnson